Q3 2022 Results

Company overview Financial review 2022 priorities Appendix References Novartis delivers solid Q3 performance across our value drivers Growth, cc Group sales Q3 +4% (YTD +5%) IM sales Q3 +4% (YTD +5%); US IM sales Q3 +8% Sandoz sales Q3 +4% (YTD +6%) 1 Innovation Productivity, cc Group core operating income Q3 +5% (YTD +6%) IM core operating income Q3 +7% (YTD +6%) IM core margin Q3 38.1%, +1.0%pts (YTD 37.1%) Sandoz core operating income Q3 -5% (YTD +5%) SG&A savings of ~USD 1.5bn to be fully embedded by 20242 3 Scemblix approved in EU for Ph+ chronic myeloid leukemia Pluvicto CHMP positive opinion for mCRPC post-taxane³ Iptacopan Ph3 PNH, clinically meaningful superiority vs anti-C53 Cosentyx positive Ph3 SUNSHINE/SUNRISE in Hidradenitis Suppurativa 2 ESG 4 Ganaplacide/lumefantrine Malaria¹ US FDA Orphan Drug and Fast Track Designation Pediatric formulation of Hydroxyurea SCD launched in Ghana Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 49 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. IM - Innovative Medicines Division SCD Sickle cell disease 1. Combination, being co-developed with Medicines for Malaria Venture, supported by EDCTP WANECAM2, for acute, uncomplicated malaria 2. Relating to streamlined organizational model. 3. Oct 2022 4 Investor Relations | Q3 2022 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation